Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
64 results about "Molecular biomarker" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Method and system for diagnosis of neuropsychiatric disorders including attention deficit hyperactivity disorder (ADHD), autism, and schizophrenia
InactiveUS20100010336A1Neurological deficit scoreNavigation performance in was impairedDiagnostic recording/measuringSensorsDiseaseAttention deficits
A method and system for medical imaging of neuropsychiatric disorders including attention deficit hyperactivity disorder (ADHD), autism, and schizophrenia. Noninvasive, in vivo methods identify novel brain molecular biomarkers of normal neurodevelopment in order to determine molecular underpinnings of abnormal neurodevelopment. The described brain molecular biomarkers will aid in the presymptomatic diagnosis of neuropsychiatric disorders which begin in childhood and adolescence, such as ADHD, autism, and schizophrenia.
Owner:PETTEGREW JAY W +1
Molecular biomarkers for cancer immunotherapy
ActiveUS20190127803A1Microbiological testing/measurementDisease diagnosisImmunotherapeutic agentOncology
In one aspect, provided herein is a method comprising: (a) (i) determining cytolytic activity in a tumor from the subject; and / or (ii) determining genetic alterations associated with cytolytic activity in the tumor; and (b) administering an immunotherapeutic agent to the subject if (i) cytolytic activity is detected in the tumor and / or (ii) a genetic alteration associated with induction of cytolytic activity, tumor resistance to cytolytic activity and / or suppression of cytolytic activity is detected in the tumor.
Owner:MASSACHUSETTS INST OF TECH +1
Gene expression profiles associated with chronic allograft nephropathy
ActiveUS20120178642A1Nucleotide librariesMicrobiological testing/measurementChronic allograft nephropathyTubular atrophy
By a genome-wide gene analysis of expression profiles of over 50,000 known or putative gene sequences in peripheral blood, the present inventors have identified a consensus set of gene expression-based molecular biomarkers associated with chronic allograft nephropathy and / or interstitial fibrosis and tubular atrophy CAN / IFTA and subtypes thereof. These genes sets are useful for diagnosis, prognosis, monitoring and / or subtyping of CAN / IFTA.
Owner:THE SCRIPPS RES INST
Aqueous phase preparation method for chitosan-quantum dot fluorescent probe
InactiveCN101962450AHigh fluorescence efficiencyGood biocompatibilityFluorescence/phosphorescenceLuminescent compositionsSolubilityBottle
The invention discloses an aqueous phase preparation method for a chitosan-quantum dot fluorescent probe, which comprises the following steps of: A, preparing solution of carboxymethyl chitosan: weighing carboxymethyl chitosan, dissolving in a beaker by using double distilled water, and fixing the volume in a bottle for later use; B, preparing solution of CdTe quantum dot: according to the concentration of CdTe quantum dot, transferring the CdTe quantum dot solution to the beaker by using a transfer pipette, adding double distilled water, regulating the pH value to be 7-13, and fixing the volume in a bottle for later use; and C, mixing the prepared carboxymethyl chitosan solution and the CdTe quantum dot solution according to different volume ratios, shaking uniformly and standing at room temperature, or performing ultrasonic wave reaction, oscillating reaction or microwave heating reaction to obtain chitosan-quantum dot fluorescent probes with corresponding luminous wavelengths and different fluorescence intensities. The preparation method has the advantages of simple operation, good water solubility of products, long stabilization time, high yield of fluorescence quantum, good cellular compatibility, and wide application in the aspects of cell and macro-molecular biomarkers.
Owner:WUHAN UNIV +1
Discrimination method for charging period of underground biodegradation heavy oil reservoir
The invention relates to a discrimination method for the charging period of an underground biodegradation heavy oil reservoir, and belongs to the field of petroleum geological exploration. According to the specific technical scheme, biomarkers with high anti-biodegradation ability and good sensitivity of crude oil charging and related parameters thereof are selected, a molecular biomarker parameter TA (I) / TA (I+II) of the underground biodegradation heavy oil maturity and a quantitative relation of TA (I) / TA (I+II) and the vitrinite reflectivity Ro are calibrated, and the charging period of biodegradation heavy oil is discriminated by employing the parameter. According to the method, based on chromatography mass spectrometry characteristics and molecular biomarker response of biodegradation crude oil, effective discrimination of the charging period of the biodegradation heavy oil can be realized, the reservoir forming process of the biodegradation heavy oil is tracked, and the problem of the calculation of the proportion of crude oil being charged in different periods for multi-period mixed crude oil is solved.
Owner:CHINA UNIV OF PETROLEUM (EAST CHINA)
Methods for diagnosing chronic kidney disease and assessing the risk of disease progression
InactiveUS20120135882A1Easy diagnosisUseful in detectionNucleotide librariesMicrobiological testing/measurementMolecular biomarkerDisease progression
Methods and compositions for diagnosing chronic kidney disease and assessing the risk of disease progression, as well as methods of screening for molecular biomarkers useful for diagnosing the likelihood of disease progression, are provided.
Owner:MT SINAI SCHOOL OF MEDICINE
Methods and Devices for Detection and Acquisition of Biomarkers
The present invention provides devices and methods for detecting and capturing molecular biomarkers from a subject in situ. Specifically, the devices contain an array of microneedles to which are attached probes specific for one or more biomarkers of interest. The devices can be used directly on a subject (e.g., via skin piercing) in detecting the biomarkers in the body of the subject (e.g., tissues, blood stream).
Owner:THE SCRIPPS RES INST +1
Noninvasive method for measuring metabolites for skin health
A noninvasive method for diagnosing skin health in a subject comprising collecting a skin sample from the subject; detecting a level of one or more small molecule biomarkers in the epithelial cell sample / skin cell sample; diagnosing the subject as having a skin condition based on the level of a detected small molecule biomarker, wherein the detected small molecule is at least one compound chosen from: a compound generated by metabolism of amino acids, a compound generated by dipeptides metabolism, a compound generated by nucleic acids, a compound generated by metabolism of lipids, a compound generated by metabolism of carbohydrates, and mixtures thereof and further small molecule biomarkers as listed in Table 1. Further, a noninvasive method for evaluating the efficacy of products for skin health.
Owner:THE PROCTER & GAMBLE COMPANY
Molecular biomarker set for early detection of ovarian cancer
ActiveUS20120231090A1Increased riskUltrasonic/sonic/infrasonic diagnosticsOrganic active ingredientsGene productOncology
Embodiments of the present invention concern methods and compositions related to detection of ovarian cancer, including detection of the stage of ovarian cancer, in some cases. In particular, the invention encompasses use of expression of TFAP2A and in some embodiments CA125 and / or E2F5 to identify ovarian cancer, including detecting mRNA and / or protein levels of the respective gene products. Kits for detection of ovarian cancer are also described.
Owner:KING ABDULLAH UNIV OF SCI & TECH
Tissue molecular signatures of kidney transplant rejection
InactiveUS20170191128A1Mechanical/radiation/invasive therapiesHealth-index calculationChronic allograft nephropathyMolecular biomarker
By a genome-wide gene analysis of expression profiles of known or putative gene sequences in kidney biopsy samples, the present inventors have identified a consensus set of gene expression-based molecular biomarkers for distinguishing kidney transplantation patients who have Acute Rejection (AR), Acute Dysfunction No Rejection (ADNR), Chronic Allograft Nephropathy(CAN), or Transplant Excellent / Normal (TX). These molecular biomarkers are useful for diagnosis, prognosis and monitoring of transplantation patients.
Owner:NORTHWESTERN UNIV +1
Prediction method of physical properties of underground biodegradable thickened oil
InactiveCN104849365AThe physical properties are obtained directlyMany operating linksComponent separationChemical compositionRelational model
The invention provides a prediction method of the physical properties of underground biodegradable thickened oil. The method comprises the steps that 1, selecting crude oil samples, extracting molecular biomarkers to carry out quantitative test analyses and comparison, and then judging biodegradation degree of crude oil; 2, screening sensitive molecule biomarker maturity parameters with high biodegradation resistance; 3, building a quantitative relationship model between the biomarker parameters and crude oil physical properties. For the crude oil from the same source rock, thermal maturity is a main determiner influencing the chemical composition and physical properties of the crude oil. According to an oil deposit geochemical principle, the molecule biomarker maturity parameters can well reflect minute maturity changes among oil deposits, while the physical properties of the underground crude oil is controlled by the thermal maturity to a great degree. Therefore the biomarker maturity parameters not influenced by biodegradation are screened to build the relationship model with the physical properties of biodegradable crude oil, thus predicting the physical properties of the underground biodegradable thickened oil.
Owner:CHINA UNIV OF PETROLEUM (EAST CHINA)
Cloning Method of Cytochrome Oxidase Gene of Peri. didentatus
InactiveCN102286498ARich sourcesLow costFermentationPlant genotype modificationTotal rnaMolecular biomarker
The invention discloses a method for cloning cytochrome oxidase gene of Nereis bidentata, which is to clone the total RNA of Nereis bidentata body wall muscle by designing specific fragment amplification and RACE amplification. The cytochrome oxidase gene of Nereis dentata can be detected by real-time fluorescent quantitative PCR technology under the stress of persistent organic pollutants. The mechanism of oxidase gene expression and regulation provides a basis, and also lays the foundation for screening molecular biomarkers for early ecological risk prediction of marine sediment environmental pollution, which is conducive to the wide application of the low-cost and abundant sources of the clamworm in environmental protection.
Owner:DALIAN OCEAN UNIV
Construction method of microbial sensor and application method of microbial sensor
PendingCN110007072AEasy to synthesizeEasy to retouchFluorescence/phosphorescenceHigh affinity bindingCulture mediums
The invention provides a construction method of a microbial sensor and an application method of a microbial sensor. The construction method comprises the steps of: the step 1, constructing an amino acid defective strain to be detected; the step 2, intercepting target gene fragments required by an LuxI / LuxR circulating amplification line for connection to obtain a plasmid comprising the circulatingamplification line based on an LuxI / LuxR system, and transforming the recombinant plasmid into an amino acid defective strain to ensure that the report gene fragments are repeatedly expressed; and the step 3, culturing the strain to a logarithmic growth phase, and performing starvation culture in a culture medium. According to the invention, the amino acid defective strain to be detected is circularly amplified and is used as a microbial sensor, the nucleic acid aptamer combined with the protein marker and having high specificity and high affinity with a protein marker is used as a 'bridge',the detection of the protein marker is converted into the detection of the amino acid to be detected, the constructed microbial sensor is used for achieving the detection of the macromolecular biomarker, and a circular amplification system is combined as a signal amplification means so that the sensitivity of quantitative detection is greatly improved.
Owner:BEIJING INSTITUTE OF TECHNOLOGYGY
Method for screening biomarkers of ionizing radiation as well as application of SZT2 protein determined by method
InactiveCN105803049AMicrobiological testing/measurementBiological testingScreening methodMolecular biomarker
Owner:CHINA INST FOR RADIATION PROTECTION
Gene expression profiles associated with chronic allograft nephropathy
By a genome-wide gene analysis of expression profiles of over 50,000 known or putative gene sequences in peripheral blood, the present inventors have identified a consensus set of gene expression-based molecular biomarkers associated with chronic allograft nephropathy and / or interstitial fibrosis and tubular atrophy CAN / IFTA and subtypes thereof. These genes sets are useful for diagnosis, prognosis, monitoring and / or subtyping of CAN / IFTA.
Owner:THE SCRIPPS RES INST
Molecular biomarker for diagnosing and treating triple-negative breast cancer and application thereof
ActiveCN112430665AFavorable meansThe value of good practical applicationMicrobiological testing/measurementAntineoplastic agentsTreatment targetsBiologic marker
The invention provides a molecular biomarker for diagnosing and treating triple-negative breast cancer and application thereof, and belongs to the technical field of crude drugs and molecular biology.The invention finds for the first time that circEIF3H expression in a tumor specimen of a patient suffering from triple-negative breast cancer is obviously higher than that of breast cancer tissues of other subtypes, meanwhile, the circEIF3H expression quantity is related to prognosis of triple-negative breast cancer, and malignant growth and invasion capacity of breast cancer cells can be controlled by regulating the circEIF3H expression. Therefore, the circEIF3H can be used as a molecular biomarker for diagnosing and treating the triple-negative breast cancer, and can be used as a prognosisindex and a potential treatment target of the triple-negative breast cancer. The biomarker provides a more favorable means for diagnosis and prognosis evaluation analysis of the triple-negative breast cancer, has important significance for research and treatment of the triple-negative breast cancer, and thus, has favorable practical application value.
Owner:SHANDONG UNIV QILU HOSPITAL
Cloning method of perinereis aibuhitensis metal binding protein gene
InactiveCN102304517ARich sourcesLow costFermentationPlant genotype modificationPerinereis aibuhitensisFluorescence
The invention discloses a cloning method of a perinereis aibuhitensis metal binding protein gene. According to the invention, a specific segment amplification method and a RACE amplification method are designed, and a perinereis aibuhitensis metal binding protein gene is cloned from perinereis aibuhitensis body wall muscle total RNA. With the method, the MP II gene expression regularity of perinereis aibuhitensis suffered from stresses of pollutants such as heavy metals can be detected with a real-time fluorescence quantitative PCR technology. Therefore, the method provides a basis for the study of the mechanism of heavy metal regulation on perinereis aibuhitensis MP II gene. Also, the method assists in establishing a basis for screening molecular biomarkers for marine sedimentary environment pollution early-stage ecological risk forecasting. With the method, perinereis aibuhitensis with a low cost and an abundant source can be widely applied in environment protection.
Owner:DALIAN OCEAN UNIV
Early NSCLC prognosis prediction system
ActiveCN112037863AImprove forecast accuracyIncreased sensitivityHealth-index calculationBiostatisticsPredicting performanceMolecular biomarker
The invention discloses an early NSCLC prognosis prediction system, which comprises a main effect identification module, an interaction identification module, a survival time prediction module and a high-dimensional population discrimination module, and can improve the model prediction precision from the perspective of cross-omics by establishing a sample database and molecular biomarkers-methylation and gene expression. Different from a traditional biomarker, the system is stable and minimally invasive, the sensitivity and specificity of prognosis prediction are greatly improved, the main effect, GxE and GxG interaction effects are integrated, an early-stage NSCLC survival prediction model which is high in prediction precision and has strict multi-stage independent crowd verification is constructed, the defect that an existing model is poor in prediction effect is overcome, and a high-risk crowd discrimination module is combined. People with different risks are discriminated, diseaseprognosis is evaluated scientifically and accurately, and clinicians are helped to make clinical decisions or guide adjuvant therapy, early intervention and early benefit.
Owner:NANJING MEDICAL UNIV
Prostate specific antigen proteolytic activity for clinical use
InactiveUS20160097082A1Improve determinationImproved prognosisBiocideMicrobiological testing/measurementAntigenProstate-specific antigen
Methods for predicting the outcome of and monitoring prostate cancer patients using prostate specific antigen (PSA) proteolytic activity (PPA) in combination with other molecular biomarkers or other parameters are described. Methods of determining sets of parameters for use in predicting the outcome of and monitoring of prostate cancer patients are also described.
Owner:OHMX CORP
Breast cancer biological molecule marker LASS2 protein, modifying product and medical composition thereof
InactiveCN101240020AImprove diagnostic accuracyHigh resolutionPeptide/protein ingredientsGenetic material ingredientsNovel treatment methodOncology
The invention relates to a protein, specifically relates to a breast cancer molecular biomarker LASS2 protein, modified product and pharmaceutical composition thereof. The inventive project is: a breast cancer molecular biomarker LASS2 protein, wherein aminoacid sequence of LASS2 is shown in SEQ ID NO: 1; application of the breast cancer molecular biomarker in preparation of diagnosis reagent and therapeutic and preventive breast cancer medication. Advantages of the invention are: the breast cancer molecular biomarker LASS2 protein has a specific high expression in breast cancer tissue of different types and differentiations, and the invention has a vital importance in establishing novel diagnosis method for breast cancer, and establishing novel treatment method using receptor guided breast cancer target medicament.
Owner:SHANGHAI JIAO TONG UNIV
Molecular biomarker set for early detection of ovarian cancer
ActiveUS9057107B2Ultrasonic/sonic/infrasonic diagnosticsOrganic active ingredientsGene productOncology
Embodiments of the present invention concern methods and compositions related to detection of ovarian cancer, including detection of the stage of ovarian cancer, in some cases. In particular, the invention encompasses use of expression of TFAP2A and in some embodiments CA125 and / or E2F5 to identify ovarian cancer, including detecting mRNA and / or protein levels of the respective gene products. Kits for detection of ovarian cancer are also described.
Owner:KING ABDULLAH UNIV OF SCI & TECH
Renal cell carcinoma biomarker and application thereof
PendingCN112553335AProlong survival timeImprove the quality of lifeMicrobiological testing/measurementDNA/RNA fragmentationSocial benefitsBiologic marker
The invention discloses a renal cell carcinoma biomarker. As a metastasis marker, the renal cell carcinoma biomarker is used for diagnosing and / or evaluating renal cell carcinoma prognosis and the risk of metastasis; or, as a specific molecular target of the renal cell carcinoma, the renal cell carcinoma biomarker is applied to treatment of the renal cell carcinoma; and the biomarker comprises oneor more of THBS2, SCGB1A1, NKX2-1, COL11A1, DCN, COL1A1 and SFTPB. By detecting the expression levels of THBS2, SCGB1A1, NKX2-1, COL11A1, DCN, COL1A1 and SFTPB in tissue of a renal cell carcinoma patient, whether the renal cell carcinoma patient has metastasis or not and prognosis can be judged, and the accuracy rate reaches 93% or more. Therefore, the disease progression, metastasis and prognosis of the renal cell carcinoma patient can be evaluated by detecting molecular biomarkers including the THBS2 and the like in the tissue of the renal cell carcinoma patient, and thus, symptomatic related treatment can be performed in time, the survival time and quality of the patient are respectively extended and improved; and the renal cell carcinoma biomarker has relatively great economic value and social benefits.
Owner:GENERAL HOSPITAL OF NUCLEAR IND
Method for Diagnosis of Bladder Cancer and Related Kits
InactiveUS20130203059A1Strong PTPD immunoreactive signalMicrobiological testing/measurementBiological material analysisBacteriuriaBladder cancer patient
The invention refers to a novel molecular biomarker, namely PTPD1, that is markedly increased in human bladder cancers. PTPD1 expression positively correlated with the grading and invasiveness potential of these tumors. PTPD1 can be detected at high levels in exfoliated bladder cells isolated from urine of bladder cancer patients, while no PTPD1 signal was evident in normal exfoliated bladder cells. Thus, PTPD1 detection in urine samples may represent a novel and reliable marker for non-invasive diagnosis of aggressive bladder cancer.
Owner:TOPOGEN
Methods and devices for detection and acquisition of biomarkers
ActiveUS9540684B2Microbiological testing/measurementWithdrawing sample devicesBiologic markerMolecular biomarker
The present invention provides devices and methods for detecting and capturing molecular biomarkers from a subject in situ. Specifically, the devices contain an array of microneedles to which are attached probes specific for one or more biomarkers of interest. The devices can be used directly on a subject (e.g., via skin piercing) in detecting the biomarkers in the body of the subject (e.g., tissues, blood stream).
Owner:THE SCRIPPS RES INST +1
Nourin molecular biomarkers diagnose angina patients with negative troponin
ActiveUS20200109454A1High sensitivityStrong specificityMedical simulationMedical data miningMolecular networkArtery diseases
The present invention provides a molecular network, devices, and assays for early diagnosis of angina patients experiencing acute chest pain with negative Troponin, and it reflects on disease progression and severity. The invention also allows for the diagnosis of angina in suspected patients with history of chest pain; differentiates between angina patients and acute myocardial infarction; as well as diagnose coronary artery disease patients from other non-cardiac and healthy individuals. The present invention indicates that the downregulation of Nourin IncCTB9H12.4 in coronary artery disease patients compared to non-cardiac and healthy controls, is significantly associated with upregulation of miR_106b and miR_137 resulting in overexpression of mRNA ANAPC11 and mRNA FTLH-17; respectively. Therefore, the invention provides a novel non-invasive good positive test to diagnose angina patients which also, has a good negative test to exclude chest pain non-angina patients and healthy individuals.
Owner:NOUR HEART
Application of plasma small extracellular vesicle miR-431-5p
ActiveCN111394447ATimely treatmentAccurate judgmentMicrobiological testing/measurementExtracellular vesicleDiabetes retinopathy
The invention relates to an application of plasma small extracellular vesicle miR-431-5p as a marker of diabetes retinopathy diagnosis. It is firstly found that the expression level of miR-431-5p in plasma sEVs is closely related to diabetes retinopathy, and whether a subject has the risk of diabetes retinopathy or not can be judged more accurately and rapidly by detecting the expression of miR-431-5p in plasma sEVs of a diabetes patient; therefore, a prevention or treatment scheme is provided for clinicians, a new diabetes target and a new treatment pathway are provided for treating diabetesretinopathy as a target for preparing drugs for treating diabetes retinopathy, and compared with a traditional detection means, the diagnosis of molecular biomarkers is more timely and specific, so that the retinopathy process of the diabetes patient is predicted, early intervention and treatment are achieved, and the application prospect is wide.
Owner:天津医科大学眼科医院
The invention also discloses application of UTIMP-2 and IGFBP-7 in preparation of biomarker for diagnosing sepsis acute kidney injury
PendingCN111413508ATroubleshoot Delayed DiagnosticsSignificant technological progressDisease diagnosisBiological testingAcute Renal InjuryMolecular biomarker
The invention provides an application of urine TIMP-2 in preparation of a biomarker for diagnosing sepsis acute kidney injury. The invention also provides application of IGFBP-7 in preparation of a biomarker for diagnosing sepsis acute kidney injury. The invention further provides application of the urine TIMP-2 combined with IGFBP-7 in preparation of a biomarker for diagnosing sepsis acute kidneyinjury. The invention further provides a kit for detecting acute kidney injury caused by sepsis diagnosis. The kit contains reagents for detecting TIMP-2 and IGFBP-7 in a body fluid sample. It is found that the content of urine IGFBP-7 and TIMP-2 in clinical sepsis AKI patients is remarkably higher than that of urine IGFBP-7 and TIMP-2 in health examination and non-AKI group patients; through ROCcurve analysis, it is found that urine IGFBP-7 and TIMP-2 have high benefits in diagnosis of acute kidney injury caused by sepsis as molecular biomarkers.
Owner:SHANGHAI EAST HOSPITAL EAST HOSPITAL TONGJI UNIV SCHOOL OF MEDICINE
Molecular Biomarkers for Predicting Response to Tyrosine Kinase Inhibitors in Lung Cancer
The invention relates to methods for determining the clinical outcome of patients suffering lung cancer and being under treatment with an EGFR inhibitor. The methods are based on the detection of the presence of mutations in the EGFR gene conferring resistance to inhibitors of the EGFR tyrosine kinase activity, wherein the appearance of said mutations in the biofluid of the patient is indicative of a high probability that the patient suffers a relapse of the disease. The invention also provides therapeutic methods for said patients.
Owner:PANGAEA BIOTECH
Renal cell carcinoma miRNA molecular marker and application thereof
ActiveCN112646885AProlong survival timeImprove the quality of lifeMicrobiological testing/measurementAntineoplastic agentsRenal Cell CancersBiologic marker
The invention discloses a renal cell carcinoma miRNA molecular marker which is used as a metastasis marker and is used for diagnosing and / or evaluating prognosis and metastasis risks of renal cell carcinoma, or as a specific molecular target of the renal cell carcinoma which is applied to treatment of the renal cell carcinoma; wherein the miRNA molecular marker comprises one or more of miR-328, miR-502 and miR-504. By detecting the expression level of miR-328, miR-502 and / or miR-504 in the tissue of a renal cell carcinoma patient, whether the renal cell carcinoma patient has metastasis or not and prognosis can be judged, and the accuracy rate reaches 95% or above. Therefore, by detecting miR-328, miR-502 and / or miR-504 and other molecular biomarkers in the tissue of the renal cell carcinoma patient, the disease progression, metastasis and prognosis of the renal cell carcinoma patient can be evaluated, related treatment can be carried out on symptoms in time, the survival time and quality of life of the patient are improved, and great economic value and social benefits are achieved.
Owner:GENERAL HOSPITAL OF NUCLEAR IND
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
InactiveUS20120316187A1Reduced expression levelOrganic active ingredientsBiocideEGFR Tyrosine Kinase InhibitorsTyrosine-kinase inhibitor
The invention relates to a method for predicting the response to the treatment with an EGFR tyrosine kinase inhibitor of a patient suffering lung cancer an carrying a mutation in the EGFR gene based on the expression levels in a sample of said patient of the BRCA1 gene wherein low BRCA1 expression levels are indicative of a positive response of a patient. This positive response is also observed in patients showing the T790M mutation in the EGFR gene which is usually associated with resistance to EGFR tyrosine kinase inhibitors.
Owner:PANGAEA BIOTECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com